Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated